Eli Lilly and CompanyvsREGENXBIO

LLY and RGNX stock compared: price, dividend, valuation and results, from SEC filings.

LLY

Eli Lilly and Company

$1,347.11

Value $1.27T

-2.29%
LLY's page

RGNX

REGENXBIO Inc.

$7.16

Value $473M

-1.10%
RGNX's page

Eli Lilly and Company (LLY) has a market value of $1.27T and REGENXBIO (RGNX) $473M. Over the last year, with dividends, LLY moved +32.0% and RGNX -36.2%. Dividend yield: LLY 0.47%, RGNX none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    LLY$1.27T

    RGNX$473M

    LLY is 2,684 times RGNX

  • Revenue, 12 months

    LLY$86.5B

    RGNX$154M

    LLY is 562 times RGNX

  • Net income, 12 months

    LLY$27.6B

    RGNX-$175M

  • Operating margin

    LLY–

    RGNX-95.7%

  • ROIC

    LLY35.5%

    RGNX-115.2%

    150.7 points apart

  • P/E

    LLY46.1

    RGNX–

  • Dividend yield

    LLY0.5%

    RGNX0.0%

    0.5 points apart

  • 5-year return

    LLY+439.8%

    RGNX-77.6%

    517.4 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

LLY+439.8%

RGNX-77.6%

020040060020222023202420252026
Returns by period
PeriodLLYWith dividendsRGNXWith dividends
1 year since November 18, 2025+32.0%Price +31.2%-36.2%Price -36.2%
3 years since November 17, 2023+132.9%+32.6% a yearPrice +128.3%-63.2%-28.3% a yearPrice -63.2%
5 years since November 18, 2021+439.8%+40.1% a yearPrice +417.0%-77.6%-25.8% a yearPrice -77.6%
10 years since November 21, 2016+1,950.7%+35.3% a yearPrice +1,662.9%-66.7%-10.4% a yearPrice -66.7%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

LLYEli Lilly and CompanyRGNXREGENXBIO

Valuation

LLYRGNX
Valuation
Price$1,347.11$7.16
Market value$1.27T$473M
Enterprise value (EV)$1.32T–
P/E46.1–
P/E, 5-year median49.9–
P/B31.63.2
EV/EBIT37.8–
Free cash flow yield1.6%–

Results and growth

LLYRGNX
Results and growth
Revenue, 12 months$86.5B$154M
Net income, 12 months$27.6B-$175M
Free cash flow, 12 months$19.7B-$155M
Earnings per share, 12 months$30.81-$3.21
Revenue growth, year on year44.7%104.5%
Revenue growth a year, past+21.6%over 5 years+2.0%over 5 years
EPS growth a year, past+27.6%over 5 years–

Margins and returns on capital

LLYRGNX
Margins and returns on capital
Gross margin83.6%–
Operating margin–-95.7%
Net margin31.9%-113.9%
ROIC35.5%-115.2%
ROE88.6%-173.5%

Balance sheet

LLYRGNX
Balance sheet
Cash$4.9B$251M
Total debt$49.5B–
Net debt / EBITDA1.2–
Interest cover38.9×-4.1×

Dividends and buybacks

LLYRGNX
Dividends and buybacks
Dividend yield0.5%–
Dividend per share, 12 months$6.34–
Dividend growth a year, past+15.2%over 5 years–
Buyback yield0.3%–
Shareholder yield0.8%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: LLY or RGNX

Didn't find what you were looking for?

Ask us
Which is bigger, Eli Lilly and Company or REGENXBIO?

By market value, Eli Lilly and Company ($1.27T) is about 2,684.2 times REGENXBIO ($473M), at today's prices.

How did LLY and RGNX stock do over the last 10 years?

Since November 21, 2016, LLY's price moved +1,662.9% and RGNX's -66.7%. With dividends: LLY +1,950.7% (+35.3% a year), RGNX -66.7% (-10.4% a year). Past returns do not predict future ones.

Which pays the higher dividend, LLY or RGNX?

The dividend yield at today's price is 0.47% for Eli Lilly and Company and none for REGENXBIO. Over the last twelve months they paid $6.34 and – per share.

Which has the higher profit margins, Eli Lilly and Company or REGENXBIO?

Over the last twelve months, the net margin was 31.9% for Eli Lilly and Company and -113.9% for REGENXBIO, and the operating margin – and -95.7%. Revenue was $86.5B and $154M.

Which is the better investment, Eli Lilly and Company or REGENXBIO?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.